Bedrijfsoverzicht
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to developing a novel class of medicines designed to engage intracellular targets that have historically been deemed inaccessible to traditional therapies. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which involves high-risk research and development aimed at creating innovative treatments for complex medical conditions. As of the latest reported data, the company holds a market capitalization of $516.84M, generates annual revenue of $25.42M, and employs a workforce of 152 individuals. These valuation and revenue figures indicate that Entrada Therapeutics is a mid-sized biotechnology firm with a significant market capitalization relative to its current revenue base, a characteristic often found in early-stage clinical companies where asset value is driven more by potential future cash flows from drug approvals than by current earnings power.
Financiële gezondheid
Entrada Therapeutics reported a revenue of $25.42M over the trailing twelve months, yet posted a net income of $-143,750,000, while its EBITDA stood at $-151,902,000. The substantial gap between the modest revenue of $25.42M and the massive net loss of $143.75M reveals an aggressive cost structure typical of biotechnology firms, where heavy expenditures on research, clinical trials, and regulatory compliance consume the majority of operating income before reaching the bottom line. The company generated free cash flow of $-76,957,752, indicating that its operational cash burn is currently outpacing its ability to generate liquidity from sales, which limits immediate financial flexibility for external expansion without further capital raises. The gross margin is reported at 0.0%, the operating margin is -3103.0%, and the profit margin is 0.0%, reflecting the intense upfront capital requirements and the pre-commercial nature of the company's pipeline where revenue does not yet cover the direct costs of goods sold or general operating expenses. Regarding liquidity, the company holds $295.70M in cash against $50.93M in debt, resulting in a debt-to-equity ratio of 16.64, which suggests a highly leveraged balance sheet relative to equity but one that is largely supported by substantial cash reserves rather than traditional bank debt obligations. The current ratio stands at 12.53, a figure that indicates robust short-term liquidity, as the company possesses more than twelve times the current assets needed to cover its current liabilities. Furthermore, the return on equity is -39.1% and the return on assets is -21.6%, metrics that reveal that management is currently destroying shareholder value and utilizing assets inefficiently in terms of profit generation, which is standard for clinical-stage biotechs but highlights the reliance on external funding rather than internal reinvestment.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive earnings, while the forward P/E is reported at -3.92, implying that the market anticipates continued negative earnings or that valuation models are relying on non-traditional metrics for this stage of development. The price-to-book ratio is 1.59, indicating that the market values the company at a premium of 59% over its net asset value, likely reflecting the high potential value of its intellectual property and clinical pipeline rather than tangible book assets. The price-to-sales ratio is 20.33, and the EV/EBITDA is -1.59, suggesting that investors are willing to pay a significant multiple of sales revenue for a company that is currently unprofitable, a common valuation strategy for biotech firms where future market capture potential outweighs current financial performance. The 52-week high is $14.36 and the 52-week low is $4.93, meaning the current market price sits within this volatile trading range, though the specific percentage below the high cannot be calculated without the exact current share price, the range demonstrates significant price discovery activity typical of speculative biotechnology stocks. The beta value is -0.15, a unique and unusual metric for a healthcare stock that suggests an inverse correlation with the broader market or indicates extreme stability relative to market movements, implying that the stock's price volatility does not move in tandem with general market indices in a standard linear fashion.
Growth & Income
Entrada Therapeutics experienced a revenue growth rate of -96.5% year-over-year, while earnings growth is listed as N/A due to the absence of prior period positive earnings for comparison. The decline in revenue indicates a contraction in sales, which is not uncommon for biotechnology companies in the clinical phase as they transition between trial stages or manage inventory and commercialization strategies before product launch. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that any available earnings are not distributed to shareholders but are instead retained to fund ongoing research and development activities. Consequently, the company reinvests its limited earnings and utilizes its cash reserves to pursue its strategic objectives rather than providing income to investors, resulting in a growth and income profile that prioritizes long-term asset accumulation and clinical progress over immediate shareholder returns.